Introduction
In 1986 70 million women worldwide used the intra-uterine contraceptive device (IUCD) (see Part 2) . Between 1.6 and 11.6% of IUCD users (see part 1) have infection with Actinomyces israelii (AI). Actinomyces is encountered from time to time in every sexually transmissible diseases clinic with periodic Papanicolaou (Pap) reports in IUCD users confirming the presence of AI. The issues of whether to treat with antibiotics or whether to remove the device or refer to the family planning clinic thus arise and confront the venereologist.
This review on AI is derived from journal articles spanning 64 years up to the present day (1992) . The main body of the review is divided into four sections. Part 1 is concerned with actinomyces in the female genital tract, focusing on detection methods, prevalence and demographic and geographic variables. The next section is involved with the effect of IUCD insertion. Part 3 is concerned with pelvic infection due to actinomyces with emphasis on clinical presentation, diagnostic criteria and risk factors. Pelvic infection in this setting, it should be emphasised, is rare. The fourth part examines the management of the infected IUCD and of pelvic infection. Laparoscopy in diagnosis, the risk of pelvic actinomyces, prevention and modern management of the latter, feature amongst some of the final issues.
Part 1 Detection methods, prevalence and demographic, behavioural and geographic variables The first report of the association of actinomyces-like organisms in the genital canals of women, employing the endocervical contraceptive device was by Barth in 1928 .' Actinomyces species are normal inhabitants of the oropharynx and possibly the bowel.2 Bhagavan3 in 1978 identified actinomyces exclusively in patients wearing an intrauterine or vaginal foreign body (intra-uterine devices and pessaries).
Actinomyces are anaerobic or microaerophilic. Dilution of samples which usually contain other anaerobes, the use of media containing 2-5 mg/l metronidazole, or special selective media are useful in achieving successful isolation. Cultures are often unsuccessful because the technique is poor, and this has persuaded many American workers to rely solely on microscopy of stained smears of material, sometimes confirming their impression by using direct immunofluorescent tech A recent study by Dybdhal5 utilised old fashioned morphology as the means of identification of actinomyces as used by Duguid, 17 and Nayar,'0 in 1985. Such traditional methods still have their advocates. Actinomyces was defined as the presence of dark, dense aggregates of uniformly sized filaments revealing distinct, acute-angle branching and radiation from a central core.5 Part 2 Effect of IUCD insertion (with reference to type of device and duration of its usage) IUCD use involved 70 million women worldwide in 1986. In India 5.8 million women were fitted with IUCDs in the years 1981-1986. 9 Valicenti states8 that an IUCD has been shown to induce a mild inflammatory response in the endometrium, with focal necrosis. This may produce an environment of anaerobiosis that encourages growth of A israelii and other anaerobic organisms. In his series of 112 cases in those patients whose IUCDs were removed and not replaced, subsequent Pap smears failed to reveal actinomyces organisms. It could be concluded that in the vast majority of cases, the organism causes a superficial infestation of the endometrium, which is associated with the menstrual period. This is in contrast to true infection with associated tissue invasion.
Pine'3 observed the presence of AI, A naeslundi, and Arachnia propionica in cervicovaginal smears from women, who did use and, who did not use an IUCD AI was commoner in women using an IUCD but, there was no evidence that the use of an IUCD influenced the presence of either A propionica or A naeslundi (AN Data from India9 suggest that prolonged use (more than 2 years) of an inert or copper IUCD promotes the overgrowth of actinomyces in the vagina and, in turn, this can be detected by routine cervical cytology.8 9 20 A fairly recent report (1989) showed that the incidence of AI in the female genital tract of IUCD users was more than doubled when the IUCD was worn for longer than 4 years. 
Part 3
Incidence of pelvic infection due to actinomyces. Clinical presentation, diagnostic criteria and risk factors
There is a need for careful differentiation between the presence of AI of the female genital tract and pelvic actinomycotic disease. The latter is very rare.
Valicenti8 stated that sporadic case reports have implicated this organism as the aetiologic agent in salpingo-oophoritis, tuboovarian abscess, and endometritis in women using IUCDs. Because the morphology of the actinomycete may be variable and dependent on growth conditions, A israelii often is confused with other Gram-positive, non-sporeforming bacilli and non-related bacteria such as clostridia, corynebacteria, listeria, and leptotrichia. Actinomycetes are not cultured or isolated readily from cervical material using basic anaerobic media, which makes confirmation difficult. Direct immunofluorescence using fluorescein isothiocyanate-labelled antisera against A israelii is sensitive and specific and has become the method of choice for positive identification.
Bhagavan and Gupta3 stated that the symptoms and signs of actinomyces in the genital tract of IUCD users, which could possibly be the harbinger of more serious pelvic actinomycosis. In this series there were: vaginal discharge in 17; pelvic pain in 4; pelvic and abdominal pain in 2; menorrhagia/ intermenstrual bleeding in 3; fever in 2; pelvic mass in 2; history of pelvic inflammatory disease (PID) in 3.
Cleghorn and Wilkinson'2 found that the detection of A israelii in the female genital tract was associated with an almost four-fold increase in the incidence of PID indicating that colonisation may progress to an infection in a small number of women in the endometrium and fallopian tubes under appropriate conditions of tissue damage. This is controversial see start of section 2. At present there is no way of predicting which IUCD patients who are colonised with AI will subsequently develop serious pelvic infection.
Leslie and Garland stated in 1991 that reports of actinomyces species in cases of PID in IUCD users has varied from 17% to 25%. 16 In association with this it must be borne in mind that the prevalence of actinomyces carriage in IUCD users (as implied in part 1) varies from 1.6% to 11.6% in different series.
Spread of AI within and without the genital tract is uncommon, but when it occurs, the right ovary and fallopian tube are most frequently affected, with or without parametrial disease. 7 The uterus appears to be relatively resistant to infection and endometrial involvement is extremely rare. in the adnexa on the right, 12 were in the adnexa on the left, nine were in the parametrium on the right, nine were in the parametrium on the left.
There is a need for sophisticated anaerobic culture from female pelvic infection or abscesses; culture from female pelvic infection or abscesses; culture for actinomyces requires prolonged incubation. There is common agreement that in PID with actinomyces infection, removal of the IUCD and antibiotics are mandatory. When actinomyces are present without any evidence of PID, some operators would treat conservatively and not remove the IUCD.5 The vast majority would, however, in this circumstance, remove the IUCD and repeat the Pap smear after the next menstrual period.8 Should it be negative, some might replace it with a fresh IUCD.
The views of Cleghorn and Wilkinson'2 are pertinent here. They state that there is no way of predicting which IUCD patients, who are colonised with AI, will subsequently develop serious pelvic infection. Therefore, all IUCD users, with symptoms of possible PID, should be screened for AI so that antibiotic treatment and/or IUCD removal can be carried out, to prevent the colonisation progressing to pelvic infection. Leslie and Garland'6 in 1991 reminded us that management of IUCD users with actinomyces is arbitrary and varies from centre to centre. They advocate 2 yearly immunofluoresence tests, of a cervical smear, and if asymptomatic actinomyces carriage is discovered, removal of the device. Earlier cervical smears would be done if the patient was symptomatic.
If the IUCD user presents with localised symptoms, then amoxycillin 500 mgs tds and metronidazole 400 mgs bd or tds doxycycline 100 mgs bd for [2] [3] weeks are given and the device is removed. Pelvic actinomyces is a potentially life threatening disease but fortunately rare.
If a pelvic mass is present, aggressive and prolonged antibiotic therapy plus possible surgery is required (see part 3). Sexually Transmissible Disease Clinics becoming "Sexual Health Centres" with Family Planning expertise may, in the future, more often take part in the removal of IUCDs. Of course, there would be simultaneously monitoring of the contraceptive wishes of the patient and this is the overriding consideration in this whole debate. 
